NCT00072163View on ClinicalTrials.gov

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

September 30, 2006

Conditions
Recurrent MelanomaStage IV MelanomaTumors Metastatic to Brain
Interventions
DRUG

temozolomide

Given orally

DRUG

thalidomide

Given orally

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma | Biotech Hunter | Biotech Hunter